Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

Related Articles by Review for PubMed (Select 20231297)

1.

Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.

Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S, Ohshima K, Nakamine H, Hirano M.

Ann Oncol. 2010 Oct;21(10):2069-74. doi: 10.1093/annonc/mdq057. Epub 2010 Mar 15.

2.

Recent advances in de novo CD5+ diffuse large B cell lymphoma.

Jain P, Fayad LE, Rosenwald A, Young KH, O'Brien S.

Am J Hematol. 2013 Sep;88(9):798-802. doi: 10.1002/ajh.23467. Epub 2013 Jun 5. Review.

PMID:
23695956
3.

CD5-positive follicular lymphoma: a case report and literature review.

Sekiguchi Y, Imai H, Wakabayashi M, Sawada T, Ichikawa K, Komatsu N, Noguchi M.

Intern Med. 2011;50(8):899-904. Epub 2011 Apr 15. Review.

4.

Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.

Knight C, Hind D, Brewer N, Abbott V.

Health Technol Assess. 2004 Sep;8(37):iii, ix-xi, 1-82. Review.

5.

[Prognostic significance of Skp2 and p27(kip) in diffuse large B cell lymphoma].

Seki R, Ohshima K, Okamura T.

Rinsho Ketsueki. 2010 Dec;51(12):1741-7. Review. Japanese. No abstract available.

PMID:
21258183
6.

De novo CD5-positive diffuse large B-cell lymphoma of the temporal bone presenting with an external auditory canal tumor.

Ogawa S, Tawara I, Ueno S, Kimura M, Miyazaki K, Nishikawa H, Yamaguchi M, Kobayashi T, Shiku H.

Intern Med. 2006;45(11):733-7. Epub 2006 Jul 3. Review.

7.

Primary hepatosplenic CD5-positive diffuse large B-cell lymphoma: a case report with literature review.

Zhang X, Sun M, Zhang L, Shao H.

Int J Clin Exp Pathol. 2013 Apr 15;6(5):985-9. Print 2013. Review.

8.

Recent advances in the understanding and management of diffuse large B-cell lymphoma in children.

Reiter A, Klapper W.

Br J Haematol. 2008 Jul;142(3):329-47. doi: 10.1111/j.1365-2141.2008.06988.x. Epub 2008 Jun 3. Review.

PMID:
18537979
9.

Stem cell transplantation for diffuse large B-cell lymphoma patients in the rituximab era.

Mounier N, Gisselbrecht C.

Curr Opin Oncol. 2011 Mar;23(2):209-13. doi: 10.1097/CCO.0b013e328342b8ad. Review.

PMID:
21169834
10.

T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma.

Aki H, Tuzuner N, Ongoren S, Baslar Z, Soysal T, Ferhanoglu B, Sahinler I, Aydin Y, Ulku B, Aktuglu G.

Leuk Res. 2004 Mar;28(3):229-36. Review.

PMID:
14687617
11.

Unresolved issues in diffuse large B-cell lymphomas.

Murawski N, Zwick C, Pfreundschuh M.

Expert Rev Anticancer Ther. 2010 Mar;10(3):387-402. doi: 10.1586/era.09.170. Review.

PMID:
20214520
12.

Primary mediastinal DLBCL: evolving biologic understanding and therapeutic strategies.

Zinzani PL, Piccaluga PP.

Curr Oncol Rep. 2011 Oct;13(5):407-15. doi: 10.1007/s11912-011-0189-5. Review.

PMID:
21789543
13.

Prognostication of diffuse large B-cell lymphoma in the rituximab era.

Ninan MJ, Wadhwa PD, Gupta P.

Leuk Lymphoma. 2011 Mar;52(3):360-73. doi: 10.3109/10428194.2010.543716. Epub 2011 Jan 28. Review.

PMID:
21275631
14.

Diffuse large B-cell lymphoma: current strategies and future directions.

Cultrera JL, Dalia SM.

Cancer Control. 2012 Jul;19(3):204-13. Review.

15.

Prevention of CNS relapse in diffuse large B-cell lymphoma.

Kridel R, Dietrich PY.

Lancet Oncol. 2011 Dec;12(13):1258-66. doi: 10.1016/S1470-2045(11)70140-1. Epub 2011 Sep 18. Review.

PMID:
21933751
16.

Tumor lysis syndrome.

Cope D.

Clin J Oncol Nurs. 2004 Aug;8(4):415-6. Review. No abstract available.

PMID:
15354929
17.

III. Applying molecular phenotyping in practice.

Johnson PW, Davies A, Jack A.

Hematol Oncol. 2013 Jun;31 Suppl 1:29-32. doi: 10.1002/hon.2063. Review. No abstract available.

PMID:
23775645
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk